Motus GI Holdings Inc (NASDAQ:MOTS) CEO Timothy P. Moran purchased 5,000 shares of the firm’s stock in a transaction on Wednesday, May 22nd. The stock was bought at an average cost of $3.38 per share, for a total transaction of $16,900.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of MOTS traded down $0.04 during mid-day trading on Friday, hitting $3.36. 41,841 shares of the company’s stock traded hands, compared to its average volume of 55,593. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.31 and a current ratio of 6.36. Motus GI Holdings Inc has a 1 year low of $2.34 and a 1 year high of $10.66. The stock has a market capitalization of $72.07 million, a PE ratio of -2.73 and a beta of 2.04.
Motus GI (NASDAQ:MOTS) last posted its earnings results on Friday, May 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.29). Research analysts forecast that Motus GI Holdings Inc will post -1.13 EPS for the current fiscal year.
Several equities analysts have recently issued reports on MOTS shares. Zacks Investment Research raised Motus GI from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research note on Tuesday, January 29th. Oppenheimer set a $10.00 target price on Motus GI and gave the company a “buy” rating in a research note on Thursday, March 28th. ValuEngine cut Motus GI from a “buy” rating to a “hold” rating in a research note on Thursday. Finally, Piper Jaffray Companies reduced their target price on Motus GI from $8.00 to $6.00 in a research note on Friday, May 10th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Motus GI presently has a consensus rating of “Buy” and a consensus price target of $9.17.
About Motus GI
Motus GI Holdings, Inc operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
Featured Story: Why do companies issue convertible shares?
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.